SCHEMBL1010218

SCHEMBL1010218

CCOC(=O)CCCc1cccc(OCc2c(C)cccc2C)c1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.58
PPARG P37231 3/20 0.58
ALOX5 P09917 1/20 0.50
SLC22A12 Q96S37 2/20 0.49
CYSLTR2 Q9NS75 1/20 0.47
CYSLTR1 Q9Y271 1/20 0.47
MAPK1 P28482 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
CYP2D6 P10635 2/20 0.43
FFAR1 O14842 1/20 0.43
TSHR P16473 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634511 0.96 PPARA (0.60) PPARAPPARGALOX5SLC22A12CYSLTR2
SCHEMBL1634988 0.95 PPARA (0.62) PPARAPPARGALOX5SLC22A12CYSLTR2
SCHEMBL1634208 0.93 PPARA (0.54) PPARAPPARGSLC22A12CYSLTR2CYSLTR1
SCHEMBL954242 0.86 FFAR1 (0.54) PPARAPPARGSLC22A12CYSLTR2CYSLTR1
SCHEMBL1010327 0.85 SLC22A12 (0.50) PPARAPPARGSLC22A12MAPK1L3MBTL1
SCHEMBL959881 0.82 CYSLTR2 (0.58) PPARAPPARGSLC22A12CYSLTR2CYSLTR1
SCHEMBL3902689 0.82 PPARA (0.60) PPARAPPARGALOX5CYSLTR2CYSLTR1
SCHEMBL1856638 0.82 PPARA (0.59) PPARAPPARGALOX5
SCHEMBL4568940 0.82 SLC22A12 (0.57) PPARAPPARGSLC22A12CYP2D6CYP4F2
SCHEMBL1634802 0.81 CYSLTR2 (0.57) PPARAPPARGSLC22A12CYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 PPARA 1930/4885PPARG 2231/4885ALOX5 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.